Diaxonhit SA Stock Other OTC
Stocks
FR0004054427
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other OTC
|
||
| - USD | - |
|
| Market Cap | 197M 229M 186M 170M 317M 21.65B 318M 2.19B 851M 11.11B 861M 842M 35.79B | P/E 2026 * |
17.3x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 165M 192M 156M 142M 266M 18.14B 267M 1.84B 713M 9.31B 722M 706M 29.99B | EV / Sales 2026 * |
0.94x | EV / Sales 2027 * | - |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | 58 | 2023-06-12 |
Olivier Bosc
DFI | Director of Finance/CFO | - | 2023-10-09 |
Maarten Penning
CTO | Chief Tech/Sci/R&D Officer | - | 2023-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 2018-12-31 | |
Michel Picot
BRD | Director/Board Member | 73 | 2019-06-26 |
| Director/Board Member | 69 | 2017-06-14 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.88% | -2.57% | -1.47% | +14.09% | 48.93B | |
| -0.40% | +1.03% | +418.57% | +527.30% | 45.01B | |
| -1.42% | +2.30% | +42.67% | +22.37% | 44.07B | |
| -1.22% | -2.31% | +4.82% | +77.49% | 40.73B | |
| -0.96% | -2.31% | +15.75% | +45.41% | 33.52B | |
| -0.21% | +9.14% | - | - | 17.77B | |
| -0.35% | -1.56% | +21.42% | +120.75% | 16.5B | |
| -1.60% | -1.35% | +11.95% | +31.06% | 14.67B | |
| -1.65% | -1.03% | +75.93% | +41.12% | 13.77B | |
| Average | -0.97% | +0.48% | +73.70% | +109.95% | 30.55B | |
| Weighted average by Cap. | -0.95% | +0.05% | +89.22% | +128.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 176M 204M 165M 151M 283M 19.3B 284M 1.96B 759M 9.9B 768M 751M 31.9B | - |
| Net income | 11.6M 13.48M 10.91M 9.97M 18.65M 1.27B 18.7M 129M 50.05M 653M 50.62M 49.52M 2.1B | - |
| Net Debt | -32M -37.19M -30.11M -27.5M -51.45M -3.51B -51.59M -356M -138M -1.8B -140M -137M -5.8B | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
